不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ocular and Orbital Involvement in Extranodal Natural Killer/T-cell Lymphoma: A Systematic Review of Clinical Outcomes and Prognostic Factors.
Ocular and Orbital Involvement in Extranodal Natural Killer/T-cell Lymphoma: A Systematic Review of Clinical Outcomes and Prognostic Factors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
结外自然杀伤/T细胞淋巴瘤(ENKTL)是一种罕见且侵袭性强的恶性肿瘤,眼部及眼眶受累是一种不常见但具有重要临床意义的临床表现。许多病例常因能够模拟常见的炎症性和感染性眼部疾病而被误诊,导致诊断延迟和较差的临床结局。本系统综述旨在评估眼部和眼眶ENKTL的临床结局及预后因素。一项符合PRISMA标准的系统综述已在国际前瞻性系统综述注册平台(PROSPERO;CRD420261348194)注册,并使用PubMed、MEDLINE、Embase和Cochrane Library从数据库建库至2026年3月19日进行检索。共纳入28项研究,约429例患者。提取了患者人口学特征、治疗、生存及预后因素的数据,并采用叙述性综合进行分析。中位生存期为6至17个月,死亡率高,且频繁报告临床迅速恶化。诊断延迟、疾病晚期、中枢神经系统受累及复发与较差的结局相关。与常规治疗相比,非蒽环类、基于天冬酰胺酶的方案与更好的疾病控制相关,尽管总体结局仍然较差。视力结局同样不理想。生存改善与早期识别、及时活检及适时启动适当治疗相关。
Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare and aggressive malignancy, with ocular and orbital involvement representing an uncommon but clinically important presentation. Many cases are frequently misdiagnosed due to their ability to mimic common inflammatory and infectious eye conditions, resulting in delayed diagnosis and poorer clinical outcomes. This systematic review aimed to evaluate clinical outcomes and prognostic factors in ocular and orbital ENKTL. A PRISMA-compliant systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261348194) and conducted using PubMed, MEDLINE, Embase, and Cochrane Library from database inception to 19 March 2026.
Twenty-eight studies comprising approximately 429 patients were included. Data were extracted on patient demographics, treatment, survival, and prognostic factors, and analysed using a narrative synthesis. Median survival ranged from six to 17 months, with high mortality and frequent reports of rapid clinical deterioration. Delayed diagnosis, advanced disease, central nervous system involvement, and relapse were associated with poorer outcomes.
Non-anthracycline, asparaginase-based regimens were associated with improved disease control compared with conventional therapies, although outcomes remained poor overall. Visual outcomes were similarly unfavourable. Improved survival was associated with early recognition, prompt biopsy, and timely initiation of appropriate treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。